JP2005500029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500029A5 JP2005500029A5 JP2003503798A JP2003503798A JP2005500029A5 JP 2005500029 A5 JP2005500029 A5 JP 2005500029A5 JP 2003503798 A JP2003503798 A JP 2003503798A JP 2003503798 A JP2003503798 A JP 2003503798A JP 2005500029 A5 JP2005500029 A5 JP 2005500029A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleotide sequence
- group
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 239000002773 nucleotide Substances 0.000 claims 28
- 125000003729 nucleotide group Chemical group 0.000 claims 28
- 108091033319 polynucleotide Proteins 0.000 claims 27
- 239000002157 polynucleotide Substances 0.000 claims 27
- 102000040430 polynucleotide Human genes 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 238000000034 method Methods 0.000 claims 16
- 102200118232 rs33959340 Human genes 0.000 claims 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 230000004071 biological effect Effects 0.000 claims 4
- 238000003205 genotyping method Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010059313 Anogenital warts Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 1
- 208000006154 Chronic hepatitis C Diseases 0.000 claims 1
- 208000000907 Condylomata Acuminata Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 108010067902 Peptide Library Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 claims 1
- 201000004201 anogenital venereal wart Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000004041 dendritic cell maturation Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009510 drug design Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 238000013537 high throughput screening Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0107588A FR2825716B1 (fr) | 2001-06-11 | 2001-06-11 | Nouveaux polynucleotides et polypeptides de l'ifn alpha 7 |
| PCT/EP2002/007456 WO2002101048A2 (en) | 2001-06-11 | 2002-06-11 | NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500029A JP2005500029A (ja) | 2005-01-06 |
| JP2005500029A5 true JP2005500029A5 (enExample) | 2005-09-22 |
Family
ID=8864156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003503798A Pending JP2005500029A (ja) | 2001-06-11 | 2002-06-11 | IFNα−7遺伝子の新規ポリヌクレオチド及びポリペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7399464B2 (enExample) |
| EP (1) | EP1395684A2 (enExample) |
| JP (1) | JP2005500029A (enExample) |
| AU (1) | AU2002317867A1 (enExample) |
| FR (1) | FR2825716B1 (enExample) |
| WO (1) | WO2002101048A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| FR2822845B1 (fr) * | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
| US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| TW202506736A (zh) | 2018-10-11 | 2025-02-16 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH657141A5 (de) | 1980-07-01 | 1986-08-15 | Hoffmann La Roche | Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen. |
| ZA814375B (en) | 1980-07-01 | 1982-07-28 | Hoffmann La Roche | Interferons and process for their preparation |
| JPH064673B2 (ja) | 1980-11-10 | 1994-01-19 | ゲネンテツク・インコ−ポレ−テツド | ハイブリド型ヒト白血球インタフエロン |
| US4801685A (en) * | 1981-08-14 | 1989-01-31 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
| EP0072541A3 (en) | 1981-08-14 | 1984-04-18 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them |
| US4810645A (en) | 1981-08-14 | 1989-03-07 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| GB2108510B (en) | 1981-10-03 | 1984-12-12 | Ciba Geigy Ag | Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof |
| EP0098864A1 (en) | 1982-01-15 | 1984-01-25 | Cetus Corporation | Interferon-alpha 74 |
| US5098703A (en) | 1982-01-15 | 1992-03-24 | Cetus Corporation | Interferon-alpha 76 |
| IE54592B1 (en) | 1982-03-08 | 1989-12-06 | Genentech Inc | Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby |
| CA1217440A (en) | 1982-08-18 | 1987-02-03 | Michael A. Innis | INTERFERON .alpha. 6L |
| IL71555A (en) | 1984-04-15 | 1992-06-21 | State Of Israel Israel Inst Fo | Bovine interferon |
| SE8502430L (sv) | 1985-05-15 | 1986-11-16 | Kabivitrum Ab | En cdna-molekyl som kodar for expressionen av en polypeptid av typen interferon alfa, en bakteriell eller celluler verd transformerad med en sadan molekyl och en polypeptid som uppvisar interferonaktivetet framstelld me |
| SU1703690A1 (ru) | 1986-04-30 | 1992-01-07 | Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов | Рекомбинантна плазмидна ДНК @ 22, кодирующа синтез интерферона @ -11 человека, и штамм бактерии РSеUDомоNаS Sp. -продуцент- интерферона @ -11 человека |
| US5780021A (en) | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
| WO1994029344A1 (en) | 1993-06-11 | 1994-12-22 | Pestka Biomedical Laboratories, Inc. | Super proteins including interferons and interleukins |
| US6001589A (en) | 1993-06-11 | 1999-12-14 | Pbl Biomedical Laboratories, Inc. | Method of identifying proteins modified by disease states related thereto |
| EP1140144A4 (en) * | 1998-12-31 | 2002-10-30 | Viragen Inc | METHODS AND COMPOSITION OF EXTREMELY PURIFIED NATURAL MIXTURES OF TYPE I INTERFERONS DERIVED FROM LEUCOCYTES |
| AU8001300A (en) * | 1999-10-07 | 2001-05-10 | Maxygen, Inc. | Ifn-alpha homologues |
| US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
| IL155741A0 (en) * | 2000-11-03 | 2003-12-23 | Pbl Biomedical Lab | Interferons, uses and compositions related thereto |
| WO2002069913A1 (en) | 2001-03-01 | 2002-09-12 | Clinical Cosmetic Co., Ltd. | Skin-improving composition set |
-
2001
- 2001-06-11 FR FR0107588A patent/FR2825716B1/fr not_active Expired - Fee Related
-
2002
- 2002-06-11 WO PCT/EP2002/007456 patent/WO2002101048A2/en not_active Ceased
- 2002-06-11 EP EP02747458A patent/EP1395684A2/en not_active Withdrawn
- 2002-06-11 AU AU2002317867A patent/AU2002317867A1/en not_active Abandoned
- 2002-06-11 JP JP2003503798A patent/JP2005500029A/ja active Pending
-
2003
- 2003-12-11 US US10/732,485 patent/US7399464B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fletcher et al. | Transcriptomic analysis of the woodchuck model of chronic hepatitis B | |
| Crow et al. | Microarray analysis of interferon-regulated genes in SLE | |
| Kaiser et al. | Differential cytokine responses following Marek's disease virus infection of chickens differing in resistance to Marek's disease | |
| Bataller et al. | Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal | |
| Waddell et al. | Dissecting interferon-induced transcriptional programs in human peripheral blood cells | |
| JP2004533240A5 (enExample) | ||
| JP2022524212A (ja) | 操作されたmRNA配列及びその使用 | |
| RU2003133982A (ru) | Новые полинуклеотиды и полипептиды гена ifn альфа-17 | |
| Zayed et al. | Association of toll-like receptor 3 and toll-like receptor 9 single nucleotide polymorphisms with hepatitis C virus infection and hepatic fibrosis in egyptian patients | |
| Steinhagen et al. | Activation of type I interferon-dependent genes characterizes the “core response” induced by CpG DNA | |
| Rani et al. | Novel interferon-β-induced gene expression in peripheral blood cells | |
| Astakhova et al. | Characterization of equine and other vertebrate TLR3, TLR7, and TLR8 genes | |
| JP2005500029A5 (enExample) | ||
| Urosevic et al. | Type I IFN innate immune response to adenovirus-mediated IFN-γ gene transfer contributes to the regression of cutaneous lymphomas | |
| JP2004535196A5 (enExample) | ||
| CN110734974B (zh) | 一种癌症化疗用药snp位点组合以及检测引物 | |
| Xiang et al. | Liver transcriptome analysis of the Sparus macrocephlus in response to Vibrio parahaemolyticus infection | |
| JP2025098004A (ja) | マクロファージ刺激1受容体(mst1r)バリアント及びその使用 | |
| JP2005500029A (ja) | IFNα−7遺伝子の新規ポリヌクレオチド及びポリペプチド | |
| Zhang et al. | De novo RNA-seq assembly and differential transcriptome analysis of Carassius auratus gibelio after Cyprinid herpesvirus 2 infection | |
| Sivaprasad et al. | The distribution of genotype and allelic frequency of IL28B gene polymorphism in Andhra Pradesh, India | |
| Li et al. | Analysis of lncRNA, miRNA, and mRNA expression profiling in type I IFN and type II IFN overexpressed in porcine alveolar macrophages | |
| CN107312828A (zh) | 与不同肿瘤生长速度肝癌相关的单核苷酸多态性位点及其应用 | |
| JP5787337B2 (ja) | C型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット | |
| Wang et al. | Generation and mapping of expressed sequence tags from virus-infected swine macrophages |